View Older Stories View More Recent Stories
-
Merck (MRK) PT Raised to $100 at Bernstein SocGen Group
-
Merck (MRK) PT Raised to $135 at Wells Fargo
-
Merck (MRK) PT Raised to $109 at Morgan Stanley
-
Merck (MRK) PT Raised to $132 at BofA Securities
-
Merck (MRK) PT Raised to $135 at BMO Capital
-
Merck shares fall as 2026 guidance disappoints despite solid Q4 results
-
Merck (MRK) Reports In-Line Q4 EPS; offers guidance
-
Merck preview: focus on post-Keytruda growth path
-
Merck (MRK) call put ratio 2.1 calls to 1 put into quarter results
-
Merck (MRK) call put ratio 1.7 calls to 1 put into quarter results
-
Merck (MRK) call put ratio 1 call to 1.9 puts into quarter results
-
Merck (MRK) call put ratio 1.7 calls to 1 put into quarter results
-
Merck Is Said To Seek $30M Stake In Eikon Therapeutics IPO - Bloomberg
-
Merck (MRK) Declares $0.85 Quarterly Dividend; 3.2% Yield
-
Truist Securities keeps Revolution (RVMD) at Buy, 'believe that RVMD is well funded and doesn't need to do a deal'
-
Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit
-
Merck ends acquisition talks with Revolution Medicines - WSJ
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
Merck (MRK) Added to BofA US 1 List, Apple (AAPL) Remains On
-
Bernstein Reiterates Market Perform Rating on Merck (MRK)
-
Merck (MRK) PT Raised to $120 at TD Cowen
-
Merck (MRK) PT Raised to $124 at Leerink Partners
-
Moderna and Merck report sustained melanoma treatment benefits at 5 years
-
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in P
-
FDA delays reviews of Sanofi's Tzield and Disc Medicine's bitopertin
-
Merck (MRK) Reiterated at Buy by UBS: Bags FDA CNPV Voucher for Sac-TMT
-
Wells lists 14 high-conviction long ideas for Q1 2026
-
STAT reported Feuerstein: meeting with Revolution Medicines CEO cancelled
-
Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ
-
Revolution Medicines (RVMD) CEO Said to Cancel Upcoming Meetings Amid M&A Chatter
-
After-hours movers: Rocket Companies, General Motors, Intel, and more
-
Merck Discussed $28B-$32B Price For Revolution Medicines - FT
-
Merck (MRK) in Talks to buy Revolution Medicines (RVMD) - FT
-
Merck (MRK) call put ratio 3.1 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe
-
Wolfe Research Upgrades Merck (MRK) to Outperform
-
Allegro MicroSystems, Inc. (ALGM) Wells Fargo 14 High-Conviction 2026 Ideas
-
BofA unveils its top 10 U.S. ideas for Q1 2026
-
BofA: 'our Top 10 Ideas include nine Buys and one Underperform across nine industries'
-
FDA awards priority vouchers to two investigational drugs
-
Merck agrees with US government to expand medicine access and cut costs
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Trump to announce prescription drug price agreements
-
At Least 7 Drug Companies to Announce Price Cuts with Trump at White House - WaPo
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
BMO Capital Upgrades Merck (MRK) to Outperform
-
FDA to fast-track reviews of two Merck drugs under commissioner national priority voucher pilot program - Reuters
-
Merck reports positive results for KEYTRUDA plus Padcev in bladder cancer
-
Merck gets EU committee backing for expanded WINREVAIR use in PAH
-
FDA launches fresh safety scrutiny of approved RSV therapies for infants - Reuters
